GlaxoSmithKline (GSK) has turned to the US for its new general counsel, hiring Sidley Austin life sciences partner Dan Troy following a seven-month search.
Former GSK general counsel Rupert Bondy joined energy company BP in May after announcing his departure in January. Troy will start at GSK on 2 September. GSK refused to confirm who is acting as interim general counsel.
Troy has been at Sidley for the past four years, serving as a partner in the life sciences practice as well as in the appellate litigation group. In addition to private practice he ;has ;experience ;of in-house legal work, having been chief counsel for the US Food and Drug Administration, where he was a primary liaison to the White House and the US Department of Health and Human Services.
Troy will report to GSK CEO Andrew Witty, who said: ;“Dan’s ;wealth ;of experience in the regulatory legislative area will be of enormous benefit to us, and ultimately to patients.”